Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2680
Título: Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
Autor: Guerreiro Castro, S
Isenberg, D
Palavras-chave: HCC MED
Belimumab
Biologic Therapy
Immunosuppressive Agents
Systemic Lupus Erythematosus
Data: Mar-2017
Editora: SAGE Publications
Citação: Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85
Resumo: Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
Peer review: yes
URI: http://hdl.handle.net/10400.17/2680
DOI: 10.1177/1759720X17690474
Aparece nas colecções:MED - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Ther Adv Musculos Dis.pdf1,06 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.